A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression (TRD). [Studio multicentrico, randomizzato, in doppio cieco, controllato verso farmaco attivo, comparativo, a dose fissa, dose-risposta per valutare l'efficacia e la sicurezza di BMS-820836 in pazienti con depressione maggiore resistente al trattamento].

Trial Profile

A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression (TRD). [Studio multicentrico, randomizzato, in doppio cieco, controllato verso farmaco attivo, comparativo, a dose fissa, dose-risposta per valutare l'efficacia e la sicurezza di BMS-820836 in pazienti con depressione maggiore resistente al trattamento].

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Liafensine (Primary) ; Duloxetine; Escitalopram
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms BMS-TRUI
  • Most Recent Events

    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Feb 2013 Planned End Date changed from 1 Jul 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 21 Aug 2012 New source identified and integrated (Clinical Trials Registry - India, CTRI2012-04-002617).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top